CompletedEarly Phase 1NCT02646319
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Studying Squamous cell carcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Mitesh BoradMayo Clinic
- Intervention
- Laboratory Biomarker Analysis(other)
- Enrollment
- 2 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2018
Study locations (2)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Mayo Clinic, Rochester, Minnesota, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02646319 on ClinicalTrials.gov